Barely Significant
← all excerpts

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.

Onco Targets Ther · 2022 · PMC9060812 · PMID 35509452

Europe PMCDOI
1
hedged sentence
0.0070
closest p · 0.1× alpha
0.0070
boldest claim

The sentences

highly significantP = 0.007actually significant
This difference was highly significant (hazard ratio, 3.3; 95% CI, 1.4–8.6; P = 0.007). 124 This has led to the preparation of a randomised, double-blinded phase II trial ( NCT03018288 ) that is actively recruiting 108 patients with newly diagnosed GBM.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.